ArticleBioengineering (Basel, Switzerland)2026
Dark-Blood Adiabatic
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
T1ρ mapping is emerging as a potential, contrast-free alternative to late gadolinium enhancement (LGE) for assessment of myocardial viability. However, strong signal contributions from the blood pool can impede quantitative evaluation at the (sub)endocardium. In this work, we study the effectiveness of dark-blood (DB) contrast in adiabatic T1ρ (T1ρ,adiab) mapping at 3T, using slice-selective and non-selective adiabatic spin-lock pulses. Adiabatic DB-T1ρ,adiab preparations consisted of an odd number of slice-selective adiabatic full passage (AFP) pulses, followed by a final, non-selective AFP pulse. This preparation induces T1ρ,adiab decay within the imaging slice while inverting the magnetization outside. A delay (δ) between preparation and imaging allowed for relaxation and inflow of the inverted blood to achieve DB contrast. Bias and precision of DB- and bright-blood (BB)-T1ρ,adiab were compared in phantom and in healthy subjects (n = 10). Blood suppression efficacy and apparent myocardial thickness in DB imaging were investigated in simulations, phantom, and in vivo. The clinical feasibility of DB-T1ρ,adiab mapping was evaluated in a small cohort of patients (n = 7) with suspected cardiovascular diseases. DB-T1ρ,adiab values were in agreement with reference BB-T1ρ,adiab values in phantom (myocardium-like vial BB: 219.27 ± 4.80 ms, DB: 218.09 ± 8.22 ms) and in healthy subjects (BB: 182.32 ± 28.27 ms, DB: 183.49 ± 45.54 ms). A moderate increase in intra-(wCVi,r) and inter-scan variability (wCVi¯) was observed in the DB method, compared with conventional BB imaging, for phantom and healthy subjects (in vivo wCVi,r BB: 15.51 ± 2.65%, DB: 24.82 ± 4.18%; in vivo wCVi¯ BB: 3.38 ± 0.86%, DB: 7.24 ± 2.55%). Longer delay times improved blood suppression in vivo for DB-T1ρ,adiab, albeit at increased intra-scan variability in phantom and in vivo (DB wCVi,r for δ = 0 ms: 4.90 ± 0.83% in phantom, 13.44 ± 2.91% in vivo, for δ = 600 ms: 8.14 ± 1.88% in phantom, 26.25 ± 5.19% in vivo). Average apparent myocardial thickness was slightly higher when using DB-T1ρ,adiab compared with BB-T1ρ,adiab (BB: 7.33 ± 2.05 mm, DB: 7.99 ± 2.46 mm). DB-T1ρ,adiab maps yielded comparable image quality to BB-T1ρ,adiab maps in patients. DB-T1ρ,adiab mapping represents an alternative to BB-T1ρ,adiab for myocardial assessment with the potential for improved visualization of the (sub-)endocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.